Could a gout drug protect hearts in type 1 diabetes?
NCT ID NCT05949281
First seen Jan 31, 2026 · Last updated May 21, 2026 · Updated 15 times
Summary
This study tests whether colchicine, a common anti-inflammatory drug, can reduce inflammation and lower the risk of heart disease in people with type 1 diabetes. About 100 adults aged 35-80 with type 1 diabetes will take either colchicine or a placebo daily for 26 weeks, with an optional 26-week extension. Researchers will track changes in blood markers of inflammation and heart health, and follow participants for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, 2900, Denmark
Conditions
Explore the condition pages connected to this study.